Evaluation of the efficacy of Si-based agent in Rheumatoid Arthritis with complicating vestibular impairment
6 affiliations
- 1Department of Otorhinolaryngology-Head and Neck Surgery, Graduate School of Medicine, The University of Osaka, Suita, Japan
- 2Department of Neuroscience and Cell Biology, Graduate School of Medicine, The University of Osaka, Suita, Japan
- 3Addiction Research Unit, Osaka Psychiatric Research Center, Osaka Psychiatric Medical Center, Osaka, Japan
- 4SANKEN, The University of Osaka, Suita, Japan
- 5Graduate School of Frontier Biosciences, Osaka University, Osaka, Japan
- 6Institute for Biomedical Sciences, Iwate Medical University, Morioka, Japan
Abstract
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent joint inflammation and progressive disability. Although current therapies have improved clinical outcomes, safer and more effective therapeutic approaches remain needed. Silicon (Si)-based agents have antioxidant and anti-inflammatory properties and have shown beneficial effects in several inflammatory disease models. Methods: We evaluated the effects of oral administration of a Si-based agent in a type II collagen-induced arthritis mouse model. Arthritis severity was assessed using an arthritis index, hindlimb oedema, and the hindlimb extension reflex test. Serum type II collagen-specific autoantibody levels were also measured. Vestibular function was evaluated using the vestibulo-ocular reflex (VOR), and inner-ear structural changes were assessed by magnetic resonance imaging and histological analysis. Results: The Si-based agent reduced arthritis-related outcomes, including the arthritis index, hindlimb oedema, and joint movement restriction, and reduced serum type II collagen-specific autoantibody levels. In contrast, no significant differences between the Si-based agent and control groups were detected in VOR-related outcomes, endolymphatic space measurements, or inner-ear histological findings. Conclusions: These findings suggest that the Si-based agent may have beneficial effects on arthritis-related manifestations. However, its effects on the vestibular function-related outcomes examined in this study were not evident. Further studies are needed to clarify the relationship between RA and vestibular dysfunction and to determine the potential therapeutic effects of Si-based agent on these complications.
Related
- Joint–brain communication in rheumatoid arthritis: glial mechanisms, pain phenotypes, and translational evidence
- Histone lactylation in fibroblast-like synoviocytes drives CXCL1-mediated immune cell recruitment in rheumatoid arthritis
- Serum Calprotectin as predictor of Rheumatoid Arthritis disease severity and Mortality
- Identification of a shared PAX5-mediated B-cell regulatory axis in inflammatory bowel disease and rheumatoid arthritis
- Thymic CT attenuation score in SAPHO syndrome: a comparative study with rheumatoid arthritis, ankylosing spondylitis, and healthy controls
BibTeX
@article{harada2026evaluation,
title = {{Evaluation of the efficacy of Si-based agent in Rheumatoid Arthritis with complicating vestibular impairment}},
author = {Shotaro Harada and Yoshihisa Koyama and Yuki Kobayashi and Takao Imai and Yoshichika Yoshioka and Hikaru Kobayashi and Hidenori Inohara and Shoichi Shimada},
journal = {PLOS One},
year = {2026},
month = nov,
doi = {10.1371/journal.pone.0361954},
url = {https://doi.org/10.1371/journal.pone.0361954},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Evaluation of the efficacy of Si-based agent in Rheumatoid Arthritis with complicating vestibular impairment
AU - Shotaro Harada
AU - Yoshihisa Koyama
AU - Yuki Kobayashi
AU - Takao Imai
AU - Yoshichika Yoshioka
AU - Hikaru Kobayashi
AU - Hidenori Inohara
AU - Shoichi Shimada
PY - 2026
DA - 2026/11/06
JO - PLOS One
DO - 10.1371/journal.pone.0361954
UR - https://doi.org/10.1371/journal.pone.0361954
AB - Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent joint inflammation and progressive disability. Although current therapies have improved clinical outcomes, safer and more effective therapeutic approaches remain needed. Silicon (Si)-based agents have antioxidant and anti-inflammatory properties and have shown beneficial effects in several inflammatory disease models. Methods: We evaluated the effects of oral administration of a Si-based agent in a type II collagen-induced arthritis mouse model. Arthritis severity was assessed using an arthritis index, hindlimb oedema, and the hindlimb extension reflex test. Serum type II collagen-specific autoantibody levels were also measured. Vestibular function was evaluated using the vestibulo-ocular reflex (VOR), and inner-ear structural changes were assessed by magnetic resonance imaging and histological analysis. Results: The Si-based agent reduced arthritis-related outcomes, including the arthritis index, hindlimb oedema, and joint movement restriction, and reduced serum type II collagen-specific autoantibody levels. In contrast, no significant differences between the Si-based agent and control groups were detected in VOR-related outcomes, endolymphatic space measurements, or inner-ear histological findings. Conclusions: These findings suggest that the Si-based agent may have beneficial effects on arthritis-related manifestations. However, its effects on the vestibular function-related outcomes examined in this study were not evident. Further studies are needed to clarify the relationship between RA and vestibular dysfunction and to determine the potential therapeutic effects of Si-based agent on these complications.
SN - 1932-6203
ER -